Netflix co-founder and chairman Reed Hastings will not stand for re-election when his board term expires in June, the company said on April 16, 2026, marking the formal end of a near-30-year association that transformed Netflix from a DVD-by-mail start-up to a global streaming giant. The announcement accompanied first-quarter results showing revenue of $12.25 billion (up about 16% year-on-year) and net income of $5.28 billion, boosted in part by a $2.8 billion termination fee after Netflix withdrew from a bid for Warner Bros. Discovery. Management warned that second-quarter earnings would fall short of analyst forecasts, sending shares down roughly 8–9% in after-hours trading. Netflix reiterated its strategic priorities — more programming, technology-led experiences including generative AI and a planned mobile revamp, and monetisation via an expanding ad business it expects to deliver about $3 billion in 2026 — while exploring live sports, video podcasts and games as growth levers. Hastings said he will focus on philanthropy and other pursuits after leaving the board.

Apple’s iPhone shipments in China rose 20% year-on-year in the first quarter of 2026, the strongest growth among major vendors, Counterpoint Research data reported on April 17. The gain lifted Apple to about 19% market share, just behind Huawei at roughly 20%, even as overall Chinese smartphone shipments fell about 4% amid supply-chain disruptions and rising memory-chip prices. Huawei posted modest 2% growth, vivo grew 2% and budget-focused rivals fell sharply — Xiaomi shipments plunged ~35%, while Oppo and Honor dipped 5% and 3% respectively. Counterpoint analysts and Reuters attributed Apple’s outperformance to demand for the iPhone 17 series, durable-brand perception, promotional pricing and tighter supply-chain control that help absorb elevated component costs. Market watchers warned the sector faces further headwinds in Q2 as vendors raise prices to protect margins. Separately, some financial houses flagged Apple’s strong AI positioning and upgraded ratings this week, though a number of models note the stock trades at a premium and insiders have reduced holdings.

PepsiCo on April 16 reported first-quarter results that topped Street expectations as its North America food business returned to volume growth. Adjusted EPS was $1.61 versus $1.55 expected and revenue rose to $19.44 billion, up 8.5% year‑on‑year. Net income attributable to the company was about $2.33 billion ($1.70 per share). Organic revenue increased 2.6%, supported by the acquisition of Poppi and new product distribution, while North America Foods volume grew roughly 2% after targeted price cuts of up to about 15% on brands including Lay’s, Doritos and Tostitos. North America beverages saw volume decline about 2.5%. Management reiterated full‑year guidance for organic revenue growth of 2–4% and core EPS growth of 4–6%, flagged ongoing inflation and geopolitical uncertainty related to the Middle East, and said systematic commodity hedges and productivity programs should provide near‑term visibility. The company also signalled a Gatorade brand restage and continued investment in growth platforms; shares and options activity rose on the news and institutional buying was highlighted in filings.

Alstom SA warned investors on April 16-17, 2026 that execution problems on large rolling-stock projects have delayed deliveries, forcing the French train maker to abandon key profit and cash-flow targets. For the year to end-March the company reported a 4% rise in sales but operating margins slipped to about 6%. Free cash flow fell to roughly €330 million from €502 million a year earlier, and Alstom said it would not meet its prior target of €1.5 billion in cumulative free cash flow through March 2027 nor achieve the previously guided 8–10% adjusted EBIT margin. The group disclosed immediate stabilisation measures and plans for deeper operational changes. The announcement rattled markets: Alstom shares plunged as much as around 30% in Paris (trading near €16.13) and its ADR also fell on US OTC trading. Management noted strong new orders growth this year, but said slower-than-expected project execution was the primary near-term headwind.

April 16, 2026 — Abbott Laboratories trimmed its full-year adjusted profit forecast after completing its acquisition of cancer-test maker Exact Sciences, saying the deal will reduce 2026 earnings by about $0.20 a share. Abbott now expects adjusted EPS of $5.38 to $5.58, down from a prior range of $5.55 to $5.80. The company reported first-quarter revenue of roughly $11.2 billion and adjusted EPS of $1.15, narrowly beating estimates. Diagnostics revenue was about $2.18 billion and medical devices revenue roughly $5.54 billion, while the nutrition business showed continued weakness. Management said the Exact Sciences purchase — valued at roughly $21–23 billion in reported coverage — could add about $3 billion in incremental sales in 2026 but has brought near-term financing and dilution pressures. The guidance revision and acquisition timing prompted an intraday share decline of around 4–6% and sparked investor concern. Abbott also noted limited logistics disruption from the Middle East conflict and said it has boosted local inventories to mitigate supply risks.